Biotech
-
In surprise result, Alzheimerâs drug from Eisai, Biogen shows benefit in large trial
The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are…
Read More » -
Biogen to pay $900 million to settle lawsuit over MS drug outreach
A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen…
Read More » -
Roche pays $70M in another bid to catch up on cancer cell therapies
Rival companies have set a standard in lymphoma and leukemia. Now the Swiss drugmaker wants to be a pioneer in cell…
Read More » -
Vertex given green light to seek US approval of CRISPR-based therapy
The company and its development partner, CRISPR Therapeutics, will begin submitting a rolling application in November. The blood disease treatment is…
Read More » -
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer…
Read More » -
Perlara CEO Ethan Perlstein on reviving a biotech and building a âY Combinator of rare diseasesâ
The CEO resuscitated the sector’s first “public benefit corporation” during the pandemic, building an unusually transparent model for biotechs. Now,…
Read More » -
Pfizer, BioNTech seek FDA clearance for updated COVID-19 booster in children
The request, if cleared, would make U.S. kids between 5 through 11 eligible to receive a "bivalent" shot targeting components…
Read More » -
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
While a long-rumored acquisition by Merck & Co. still hasn’t materialized, Seagen is forging ahead with a deal of its own, grabbing rights…
Read More » -
Prime Medicine becomes the next high-profile biotech to test the IPO waters
The startup, which launched last year with $315 million in funding and plans to advance a new form of gene…
Read More » -
GSK names Julie Brown, former Burberry executive, its first female CFO
The U.K. drugmaker now also stands to become the first big pharmaceutical company to have women in its top two…
Read More »